• Mutation; HGNC; 1092; FOXL2; Simple; p.Cys134Trp (c.402C>G); ClinVar=VCV000376348; Zygosity=Heterozygous (PubMed=19956657; PubMed=20098707).
  

PubMed=11145608; DOI=10.1210/endo.142.1.7862
Nishi Y., Yanase T., Mu Y.-M., Oba K., Ichino I., Saito M., Nomura M., Mukasa C., Okabe T., Goto K., Takayanagi R., Kashimura Y., Haji M., Nawata H.
Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor.
Endocrinology 142:437-445(2001)

PubMed=15541573; DOI=10.1016/j.mce.2004.04.018
Havelock J.C., Rainey W.E., Carr B.R.
Ovarian granulosa cell lines.
Mol. Cell. Endocrinol. 228:67-78(2004)

PubMed=18980698; DOI=10.1186/1471-2407-8-319
Imai M., Muraki M., Takamatsu K., Saito H., Seiki M., Takahashi Y.
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
BMC Cancer 8:319.1-319.10(2008)

PubMed=19956657; DOI=10.1371/journal.pone.0007988
Schrader K.A., Gorbatcheva B., Senz J., Heravi-Moussavi A., Melnyk N., Salamanca C.M., Maines-Bandiera S.L., Cooke S.L., Leung P.C.K., Brenton J.D., Gilks C.B., Monahan J., Huntsman D.G.
The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.
PLoS ONE 4:E7988-E7988(2009)

PubMed=20098707; DOI=10.1371/journal.pone.0008789
Benayoun B.A., Caburet S., Dipietromaria A., Georges A., D'Haene B., Pandaranayaka P.J.E., L'Hote D., Todeschini A.-L., Krishnaswamy S., Fellous M., De Baere E., Veitia R.A.
Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G).
PLoS ONE 5:E8789-E8789(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)